New Drug Approved for Gaucher Disease

powered by healthline

Average Ratings

An inherited metabolic disorder

TUESDAY, Aug. 18 (HealthDay News) -- A new drug can be used to treat patients with a rare genetic disorder called Gaucher disease before the drug gets full marketing approval, according to the U.S. Food and Drug Administration.

The Associated Press reported that the agency approved a treatment protocol that allows Protalix BioTherapeutics Inc. to give prGCD to patients in a clinical trial during a shortage of an older drug called Cerezyme, made by Genzyme Corp. That company had to discard most of its ingredients for Cerezyme after an FDA inspection of the manufacturing facility.

Under the treatment protocol, the patients in the clinical trial will receive prGCD for free until the drug receives full FDA approval, the AP reported.

Gaucher disease can cause liver and neurological problems.

More information

To learn more about Gaucher disease, visit the U.S. National Institute of Neurological Disorders and Stroke.



Copyright © 2009 ScoutNews, LLC. All rights reserved.
Article from
Top of page
General Drug Tools
General Drug Tools view all tools
Tools for
Healthy Living
Tools for Healthy Living view all tools
Search Tools
Search Tools view all tools
Insurance Plan Tools
Insurance Plan Tools view all tools

What is a reference number?

When you register on this site, you are assigned a reference number. This number contains your profile information and helps UnitedHealthcare identify you when you come back to the site.

If you searched for a plan on this site in a previous session, you might already have a reference number. This number will contain any information you saved about plans and prescription drugs. To use that reference number, click on the "Change or view saved information" link below.

You can retrieve information from previous visits to this site, such as saved drug lists and Plan Selector information.